Discover ara 290 peptide 10 mg

ARA 290  Peptide

Category: Erythropoietin-Derived Innate Repair Receptor Agonist Form: Lyophilized powder Intended Use: Laboratory research only — not for human or animal consumption

Overview

ARA-290, also known by its investigational name cibinetide, is an 11-amino-acid synthetic peptide engineered from the helix-B surface region of erythropoietin (EPO). It was designed to selectively activate the innate repair receptor (IRR) — a heteromeric complex of the EPO receptor and the beta-common receptor (CD131) — without engaging the classical homodimeric EPO receptor responsible for red blood cell production. This structural distinction is the peptide’s defining research feature: it allows investigation of EPO’s tissue-protective, anti-inflammatory, and anti-apoptotic signaling in isolation from its erythropoietic (blood cell-stimulating) activity. It is supplied here strictly as a raw research compound for qualified laboratory use.

Specifications of ara 290 peptide

• Purity: ≥98% (see Certificate of Analysis for batch-specific results)
• Sequence length: 11 amino acids
• CAS number: 1208243-50-8
• Appearance: White lyophilized powder
• Storage: Store lyophilized powder at -20°C; keep reconstituted solution refrigerated at 2–8°C and use within the timeframe specified on the Certificate of Analysis
• Packaging: [vial size/quantity — insert per SKU]

Quality Assurance

Each batch is accompanied by a third-party Certificate of Analysis (COA) verifying purity and identity. COAs are available on request or via the product page prior to purchase.

Research Applications

ARA-290 has been referenced in published literature on innate repair receptor signaling, including:

• Small fiber neuropathy research — early-phase human studies in sarcoidosis-associated small fiber neuropathy have reported increased corneal nerve fiber density and reduced neuropathic pain measures
• Inflammatory signaling — preclinical work reports suppression of pro-inflammatory cytokines and inhibition of NF-κB signaling
• Tissue-protection models — published studies include preclinical work on cisplatin-induced kidney injury and cardiac inflammation in animal models
• Diabetic neuropathy and retinal research — additional preclinical interest exists in these areas, though data remains early-stage

ARA-290 previously held FDA orphan drug designation for sarcoidosis-associated small-fiber neuropathy under a now-discontinued development program; no New Drug Application was ever submitted, and there is no active IND. It has not completed clinical development and is not an approved therapy anywhere.

Important Notice ara 290 peptide

This product is sold exclusively for laboratory and research purposes. It is not approved by the FDA, MHRA, or any regulatory body for human or veterinary use, and is not a drug, dietary supplement, or cosmetic. It must not be used for diagnostic, therapeutic, or any other human or animal application. By purchasing, the buyer confirms they are a qualified researcher or institution acquiring this product for legitimate research use only, and assumes full responsibility for compliance with all applicable laws and regulations governing its handling and use.